PubMed Central, : RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2014 April; 5(2): e0010. ISSN: 2076-9172Published online 2014 April 28. doi: 10.5041/RMMJ.10144.

Table 1.

Characteristics of TORS Studies Included in the Review

TORS Study	Year	Number of Patients	Follow-up (Months)	Final Negative Margins	HPV Status	Adjuvant Treatment
TORS Study	Year	Number of Patients	Follow-up (Months)	Final Negative Margins	HPV Status	None	RT Alone	CRT
Cohen et al.²⁰	2011	50	24	47 (94%)	HPV-positive: 37/50 (74%)	9 (18%)	12 (24%)^*	27 (54%)^*
Weinstein et al.⁵³	2010	31	24	31 (100%)		7 (22%)	12 (39%)	12 (39%)
Park et al.⁵⁶	2013	39 oropharyngeal carcinoma of various types (32 OPSCC)	24	37 (95%)		14 (35.9%)	21 (53.85%)	4 (10.25%)
Cognetti et al.⁵⁸	2012	30	18	29 (97%)		8 (26%)	11 (37%)	11 (37%)
Hurtuk et al.⁵⁹	2011	54	11.8	50 (92.6%)		5 (9%)	15 (28%)	34 (63%)
Weinstein et al.⁶¹	2010	47	26	46 (98%)		5 (10.6%)	18 (38.3%)	24 (51%)
Genden et al.⁶²	2011	30	18	30 (100%)		5 (17%)	11 (36%)	14 (47%)
White et al.⁶³	2010	89 HNSCC of all sub-sites (77 OPSCC)	24	89 (100%)		33 (37%)	13 (15%)	43 (48%)
Moore et al.⁶⁸	2012	66	36	65 (98.5%)	HPV-positive: 44/61 (72.1%)	11 (16.7%)	14 (21.2)	41 (62.1%)

^* 2 more patients (4%) received adjuvant chemotherapy.

CRT chemotherapy and radiation therapy; HNSCC, head and neck squamous cell carcinoma; HPV human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma; RT, radiation therapy; TORS, transoral robotic surgery.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2014 April; 5(2): e0010. ISSN: 2076-9172

Published online 2014 April 28. doi: 10.5041/RMMJ.10144